Title : Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer.

Pub. Date : 2020 May

PMID : 31332704






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 After adjusting for performance status, age and the presence of brain metastasis at baseline, treatment with pemetrexed-based platinum doublet was associated with an increased risk of death [HR 2.27 (95% CI 1.12-4.63), P = 0.02] among KRAS-mutant patients in multivariate analysis. Platinum KRAS proto-oncogene, GTPase Homo sapiens